IRISINE’S CONCENTRATION IN PATIENTS WITH OBESITY, TYPE 2 DIABETES WITH DIFFERENT BODY WEIGHT
Keywords:irisin, obesity, type 2 diabetes, insulin resistanc
Irisin is a myokin produced in muscle, adipose tissue, controls energy and carbohydrate homeostasis and is associated with an unfavorable metabolic profile. The aim of our study was to investigate the concentration of irisin in persons with obesity and type 2 diabetes with different body weight, study the mutual influence between these myokin and BMI, carbohydrate metabolism and insulin resistance.
Materials and methods: 22 persons with obesity (age: 51.31±5.42 years; BMI: 36.38±3.49 kg/m2) and 32 patients with comorbidity obesity and type 2 diabetes (age: 52.56±7.69 years, BMI: 36.51±3.75 kg/m2; HbA1c: 9.97±2.02%), 32 patients with type 2 diabetes with a normal body mass (age: 53.25±5.52 years; BMI: 23.1±2.41 kg/m2; HbA1c: 9.09±1.95%) and the control group (age: 50.81±6.8 years; BMI: 22.73±1.85 kg/m2; HbA1c: 5.25±0.44%) were examined.
The serum concentration of irisin was determined by the immunoenzyme assay. The results were presented as mean±standard deviation (M±SD). Methods of variation and descriptive statistics were used. t-Student's criterion was used to determine the reliability of the differences between average values. Correlation analysis using the Pearson coefficient and a multifactorial regression analysis conducted.
Results: serum concentration of irisin increased in persons with obesity (10.92±3.22 ng/ml) by 26.38%, reduced in patients with obesity and type 2 diabetes (5.02±2.33 ng/ml) by 41.89%, and in type 2 diabetes patients with a normal body weight (5.47±2.64 ng/ml) on (5.47±2.64 ng/ml) compared to control group. The BMI affects on the concentration of irisin, as in the group of persons with obesity (r=0.57; p=0.001; R2=0.49) and in patients with comorbidity of obesity and type 2 diabetes (r=0.27; p=0.009; R2=0.43). The content of the irisin was influenced by the level of glucose in the group of patients with comorbidity of obesity and type 2 diabetes (r=-0.55; p=0.009; R2=0.59), and the level of glucose, HbA1c (r=-0.52; p=0.03 and r=-0.39; p=0.001; R2=0.73) - in a type 2 diabetes patients with a normal body weight.
The irisin’s content influenced insulin resistance indicators: in persons with obesity - on insulin content (r=3.87; p<0.0001; R2=0.54) and index Caro (r=-0.2; p=0.004; R2=0.54); in patients with comorbidity of obesity and type 2 diabetes (r=-6.53; p=0.00025; R2=0.56) and HOMA-IR (r=-7.27; p=0.004; R2=0.75); in 2 type diabetes patients with a normal body weight - on the content of insulin (r=-4.94; p<0.0001; R2=0.6), HOMA-IR (r=-6.17; p<0,0001; R2=0.74) and index Caro (r=-0.46; p<0.0001; R2=0.42).
Conclusions: Obesity is accompanied by an increase in irisin concentration, which is associated with BMI. Overweight affects irisin content in comorbidity obesity and type 2 diabetes, but the serum level of this myokin is reduced. The level of irisin is also lowered in type 2 diabetes with normal body weight. Hyperglycemia may cause a decrease of irisin’s concentration at type 2 diabetes, both comorbidity with obesity and normal body weight. Irisin is associated with insulin resistance and can affect its indicators, both in obesity and type 2 diabetes.
Shareef N, Abduljalal MH. Ann College Med, Mosul 2021;42(2): 177-183. https://doi.org/10.33899/mmed.2020.128256.1045
Huh JY, Panagiotou G, Mougios V, et al. Metabolism 2012;61(12): 1725-1738. https://doi.org/10.1016/j.metabol.2012.09.002
Schumacher MA, Chinnam N, Ohashi T, et al. Biol Chem 2013;288(47): 33738-33744. https://doi.org/10.1074/jbc.M113.516641
Vaughan RA, Gannon NP, Mermier CM, Conn CA. J Physiol Biochem 2015;71(4): 679-689. https://doi.org/10.1007/s13105-015-0433-9
Boström P, Wu J, Jedrychowski MP, et al. Nature 2012;481: 463-468. https://doi.org/10.1038/nature10777
Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Endocrine 2018;59: 260-274. https://doi.org/10.1007/s12020-017-1476-1
Chen JQ, Huang YY, Gusdon AM, Qu S. Lipids Health Dis 2015;14: 2. https://doi.org/10.1186/1476-511X-14-2
Moreno M, Moreno-Navarrete JM, Serrano M, et al. PLoS One 2015;10(4): e0124100. https://doi.org/10.1371/journal.pone.0124100
Kurdiova T, Balaz M, Vician M, te al. BJ Physiol 2014;592(5): 1091-1107. https://doi.org/10.1113/jphysiol.2013.264655
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, et al. Diabetologia 1985;28(7): 412-419. https://doi.org/10.1007/BF00280883
Caro JF. J Clin Endocrinol Metab 1991;73(4): 691-695. https://doi.org/10.1210/jcem-73-4-691
Jia J, Yu F, Wei-Ping W. World J Clin Cases 2019;7(12): 1444-1455. https://doi.org/10.12998/wjcc.v7.i12.1444
Guo X, Xuan X, Zhao B, et al. Int J Diab Develop Countries 2020: 1-7. https://doi.org/10.1007/s13410-019-00772-9
Crujeiras AB, Zulet MA, Lopez-Legarrea P, et al. Metabolism 2014;63(4): 520-531. https://doi.org/10.1016/j.metabol.2013.12.007
Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Nat Rev Endocrinol 2017;13(6): 324-337. https://doi.org/10.1038/nrendo.2016.221
Song R, Zhao X, Zhang DQ, et al. Diab Res Clin Pract 2021;175: 108788. https://doi.org/10.1016/j.diabres.2021.108788
Matsuo Y, Gleitsmann K, Mangner N, et al. J Cachexia Sarcopenia Muscle 2015;6(1): 62-72. https://doi.org/10.1002/jcsm.12006
Huerta AE, Prieto-Hontoria PL, Fernández-Galilea M, et al. J Physiol Biochem 2015;71: 547-558. https://doi.org/10.1007/s13105-015-0400-5
Wang L, Song J, Wang C, et al. J Diabetes Res 2016;2016: 2616539. https://doi.org/10.1155/2016/2616539
Yang M, Chen P, Jin H, et al. Diabetol Metab Syndr 2014;6(1): 133. https://doi.org/10.1186/1758-5996-6-133